Junshi Biosciences, an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that U.S. Food and Drug Administration has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma.
January 24, 2021
· 5 min read